City of Hope cancer Center

Duarte, California 91010-3012

6 studies enrolling now · 37 studies all time

What they study most

Adenoid Cystic Carcinoma, Adult Solid Tumor, Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Advanced Cholangiocarcinoma, Advanced Solid Tumor, Advanced Solid Tumors, Biliary Tract Cancer, Biliary Tract Neoplasms, Bladder Cancer, Breast Cancer, COVID-19, Cancer-related Problem/Condition

Studies at this site

• A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma — Recruiting now
• A Long-term Extension Study of PCI-32765 (Ibrutinib) — Recruiting now
• A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors — Recruiting now
• IVIG for Infection Prevention After CAR-T-Cell Therapy — Recruiting now
• Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study — Recruiting now
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors — Recruiting now
• A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors — Recruiting now
• A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma — Running, not enrolling
• Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) — Running, not enrolling
• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) — Running, not enrolling
• A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants — Completed
• CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease — Completed
• A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer — Stopped early
• Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers — Completed
• Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations — Running, not enrolling
• Copanlisib Plus Venetoclax in R/R DLBCL — Running, not enrolling
• A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) — Running, not enrolling
• Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) — Running, not enrolling
• Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC — Running, not enrolling
• A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases — Completed
• Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas — Completed
• Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) — Completed
• A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer — Completed
• Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma — Paused
• Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma — Completed
• Systematic Light Exposure for Fatigue in Breast Cancer Patients — Completed
• Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC — Stopped early
• A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer — Completed
• Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer — Completed
• Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma — Completed
• TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy — Stopped early
• Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer — Completed
• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas — Stopped early
• A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) — Completed
• Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer — Completed
• Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma — Completed
• Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer — Completed